WebMar 30, 2024 · Conclusions: Pembrolizumab demonstrated clinically meaningful and durable benefit, with a high ORR of 30.8%, long median duration of response of 47.5 months, and manageable safety across a range of heavily pretreated, advanced MSI-H/dMMR noncolorectal cancers, providing support for use of pembrolizumab in this setting. WebOct 25, 2024 · Meanwhile, pilocarpine-based treatments from Orasis Pharma and Eyenovia, as well as a pilocarpine/phentolamine combination in development at Ocuphire Pharma, all in phase 3, suggest Novartis...
Mona Hassan Ghattass on LinkedIn: Novartis Kisqali® Phase III …
WebSep 10, 2024 · Basel, September 10, 2024 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx ® (secukinumab) demonstrated rapid and sustained relief... WebMar 31, 2024 · Phase Phase 3 Overall status Recruiting Start date Sep 30, 2024 Completion date Jan 01, 2026 Gender All Age (s) 18 Years and older (Adult, Older Adult) Interventions Drug NIS793 Concentrate for solution infusion (Liquid in Vial) Drug Nab-paclitaxel Per locally approved formulation Drug Gemcitabine Per locally approved formulation Drug Placebo raycap 3315-alm-rs485
Lp(a) HORIZON achieves 50% enrollment in trial to assess …
WebApr 14, 2024 · In total, 827 patients with advanced, recurrent, or metastatic endometrial cancer (EC) were randomly assigned to receive lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously once every 3 weeks (n = 411) or chemotherapy of the treating physician's choice (doxorubicin 60 mg/m 2 intravenously once every 3 weeks or … WebJul 20, 2024 · Lp(a) HORIZON is a global, multicenter, double-blind, placebo-controlled pivotal Phase 3 study conducted by Novartis. The study is designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a) with 80 mg of pelacarsen administered monthly via subcutaneous administration. WebMar 26, 2024 · Phase 3. Detailed Description: The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to placebo and standard of care in patients … raycap 3315